ANDA 218342, held by Umedica. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 218342 (Sertraline Hydrochloride), held by Umedica, was first approved by FDA on Jan 20, 2026, with 0 approved supplements and 0 published complete response letters.
Sertraline Hydrochloride (HCl) Capsules is indicated for the treatment of the following: Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older Sertraline Hydrochloride (HCl) Capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of: Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2026 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 150MG BASE · capsule;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 200MG BASE · capsule;oral | Sertraline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters